GMAB News and Press, Genmab A/S From 03/23/24

2024-03-23 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-15 09:26:51 ET More on Genmab Genmab: Recent Updates Support The Growth Narrative Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) AbbVie/ Genmab win FDA priority review for lymp...

FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL) ...

2024-02-23 14:08:15 ET More on Genmab Genmab: Recent Updates Support The Growth Narrative Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab reports FY results Genmab FY 202...

2024-02-21 03:44:55 ET Summary Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024. The company's pipeline includes promising candidates and collaborations with industry giants, supporting future ...

2024-02-20 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-14 16:17:11 ET Genmab A/S (GMAB) Q4 2023 Results Conference Call February 14, 2024 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President and Chief Executive Officer Anthony Mancini - Executive Vice President & COO Anthony Pagano -...

2024-02-14 12:59:28 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Genmab reports FY results Genmab FY 2023 Earnings Preview Seeking Alpha’s Quant ...

2024-02-14 11:29:41 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Genmab FY 2023 Earnings Preview Pfizer-Genmab cervical cancer drug gets accepted for EU review ...

Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for...